WitrynaA Phase Ib/IIa, randomized, double-blind placebo-controlled, multicenter adaptive design clinical trial to evaluate the immune signature of the treatment with the Imotope™ IMCY-0098 and its effect on the preservation of beta-cell function in young adult and adolescent patients with a recent onset Type 1 diabetes Witryna3 lut 2024 · The IMPACT trial, in collaboration with INNODIA, will evaluate the ability of the ImotopeTM IMCY-0098 to preserve beta-cell function in adult and adolescent patients with recent onset T1D as well as determine the best and safe dose and regimen for continued development. LIEGE, BELGIUM / ACCESSWIRE / February 3, 2024 / …

Clinical trial to test treatment for recent onset Type 1 Diabetes

WitrynaThis is a Phase Ib/IIa randomised, double-blind, multi-centre, adaptive design study, comparing IMCY-0098 and placebo in adult and adolescent participants with recent onset Type I diabetes (T1D). This study is designed to be conducted in two steps: Step 1 will include 24 patients aged 18-45 who will be randomised 1:1:1 to treatment with 450 µg ... Witryna2 mar 2024 · IMCY-0098 is the company’s lead product candidate and a proinsulin-derived Imotope, which has been developed stop the progression and prevent early-onset Type 1 diabetes (T1D). The multi-centre, double-blind, randomised, placebo-controlled, dose comparison trial will assess the proof-of-concept efficacy of IMCY … food and bev seta vacancies

Imcyse Reports Positive Immune Response from Interim

Witryna1 mar 2024 · Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced completion of patient enrollment in its Phase 2 IMPACT (IMCY-0098 Proof of ACtion in Type 1 Diabetes) trial of its lead … Witryna1 mar 2024 · Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment … Witryna10 kwi 2024 · 15. IMCY-0098: ImCyse 16. Drug profiles in the detailed report….. 17. Pre-clinical and Discovery Stage Products 18. ENT-001: Enthera 19. Drug profiles in the detailed report….. 20. Inactive ... food and beverage wholesalers